Research
Energy balance
Several agencies have approved tirzepatide for the treatment of type 2 diabetes and obesity.
Tirzepatide is a viable treatment option that is recognized by regulatory agencies for managing type 2 diabetes and obesity.
StrongSupportsmedium confidence
Based on data from phase 3 clinical trials, several agencies have approved its use for the treatment of type 2 diabetes and obesity.
Why this rating
Based on data from phase 3 clinical trials.
Source
The preclinical discovery and clinical evaluation of tirzepatide for the treatment of type 2 diabetes
Ioannis Avgerinos et al. · Expert Opinion on Drug Discovery · 2024
DOI 10.1080/17460441.2024.2324918
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →